Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Jun;7(6):605–611. doi: 10.1111/j.1365-2125.1979.tb04650.x

A comparison of the clinical and psychological effects of diazepam and amylobarbitone in anxious patients.

C Z Tansella, M Tansella, M Lader
PMCID: PMC1429679  PMID: 380615

Abstract

1. Twenty-four anxious inpatients were treated with diazepam, amylobarbitone sodium and placebo in flexible dosage for 1 week. They each received all three treatments according to a fully-balanced design, using double-blind procedures. 2. The clinical and the psychological effects of the drugs were assessed by the comprehensive battery of psychiatrist's ratings, subjective and psychological tests before treatment and at the end of each week of treatment. The tests included self-rating of anxiolytic and hypnotic effects, reaction-time, card sorting, coding and cancellation tasks, arithmetic and tappin. 3. Diazepam improved significantly subjective anxiety and insomnia, while amylobarbitone improved only the self-rated quality of sleep. Occasion effects were absent on clinical measures, indicating that the patients did not respond to non-specific temporal factors. Performance on motor tasks improved over time because of the expected practice effect, but an impairment relative to placebo was detected on two motor tests after the barbiturate and on four other tests with a cognitive component after the benzodiazepine.

Full text

PDF
605

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bond A. J., James D. C., Lader M. H. Sedative effects on physiological and psychological measures in anxious patients. Psychol Med. 1974 Nov;4(4):374–380. doi: 10.1017/s0033291700045815. [DOI] [PubMed] [Google Scholar]
  2. Bond A. J., Lader M. H. Residual effects of flunitrazepam. Br J Clin Pharmacol. 1975 Apr;2(2):143–150. doi: 10.1111/j.1365-2125.1975.tb01569.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bond A. J., Lader M. H. Residual effects of hypnotics. Psychopharmacologia. 1972;25(2):117–132. doi: 10.1007/BF00423189. [DOI] [PubMed] [Google Scholar]
  4. Bond A. J., Lader M. H. The residual effects of flurazepam. Psychopharmacologia. 1973 Sep 28;32(3):223–235. doi: 10.1007/BF00422145. [DOI] [PubMed] [Google Scholar]
  5. Bonn J. A., Salkind M. R., Rees W. L. A technique in the evaluation of psychotropic medication based on a patient demand schedule: comparison of the efficacy of oxypertine, diazepam and placebo in anxiety. Curr Ther Res Clin Exp. 1971 Sep;13(9):561–567. [PubMed] [Google Scholar]
  6. Dasberg H. Oral diazepam in hospitaized anxiety patients (with observations on concentration-effect-relationships). Pharmakopsychiatr Neuropsychopharmakol. 1975 Jul;8(4):162–169. doi: 10.1055/s-0028-1094455. [DOI] [PubMed] [Google Scholar]
  7. HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x. [DOI] [PubMed] [Google Scholar]
  8. Haider I. A double-blind controlled trial of a non-barbiturate hypnotic-nitrazepam. Br J Psychiatry. 1968 Mar;114(508):337–343. doi: 10.1192/bjp.114.508.337. [DOI] [PubMed] [Google Scholar]
  9. Hesbacher P. T., Rickels K., Hutchison J., Raab E., Sablosky L., Whalen E. M., Phillips F. J. Setting, patient, and doctor effects on drug response in neurotic patients. II. Differential improvement. Psychopharmacologia. 1970;18(2):209–226. doi: 10.1007/BF00401501. [DOI] [PubMed] [Google Scholar]
  10. LASAGNA L. A comparison of hypnotic agents. J Pharmacol Exp Ther. 1954 May;111(1):9–20. [PubMed] [Google Scholar]
  11. Lader M. H., Bond A. J., James D. C. Clinical comparison of anxiolytic drug therapy. Psychol Med. 1974 Nov;4(4):381–387. doi: 10.1017/s0033291700045827. [DOI] [PubMed] [Google Scholar]
  12. Malpas A., Legg N. J., Scott D. F. Effects of hypnotics on anxious patients. Br J Psychiatry. 1974 May;124(0):482–484. doi: 10.1192/bjp.124.5.482. [DOI] [PubMed] [Google Scholar]
  13. Malpas A., Rowan A. J., Boyce C. R., Scott D. F. Persistent behavioural and electroencephalographic changes after single doses of nitrazepam and amylobarbitone sodium. Br Med J. 1970 Jun 27;2(5712):762–764. doi: 10.1136/bmj.2.5712.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Maxwell A. E., Pilliner A. E. Deriving coefficients of reliability and agreement for ratings. Br J Math Stat Psychol. 1968 May;21(1):105–116. doi: 10.1111/j.2044-8317.1968.tb00401.x. [DOI] [PubMed] [Google Scholar]
  15. Moore N. C. Medazepam and the driving ability of anxious patients. Psychopharmacology (Berl) 1977 Mar 23;52(1):103–106. doi: 10.1007/BF00426608. [DOI] [PubMed] [Google Scholar]
  16. Perkins R., Hinton J. Sedative or tranquillizer? A comparison of the hypnotic effects of chlordiazepoxide and amylobarbitone sodium. Br J Psychiatry. 1974 May;124(0):435–439. doi: 10.1192/bjp.124.5.435. [DOI] [PubMed] [Google Scholar]
  17. Robin A., Curry S. H., Whelpton R. Clinical and biochemical comparison of clorazepate and diazepam. Psychol Med. 1974 Nov;4(4):388–392. doi: 10.1017/s0033291700045839. [DOI] [PubMed] [Google Scholar]
  18. Saario I., Linnoila M., Mattila M. J. Modification by diazepam or thioridazine of the psychomotor skills related to driving: a subacute trial in neurotic out-patients. Br J Clin Pharmacol. 1976 Oct;3(5):843–848. doi: 10.1111/j.1365-2125.1976.tb00636.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Salkind M. R., Silverstone T. A clinical and psychometric evaluation of flurazepam. Br J Clin Pharmacol. 1975 Jun;2(3):223–226. doi: 10.1111/j.1365-2125.1975.tb01579.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. TAYLOR J. A. A personality scale of manifest anxiety. J Abnorm Psychol. 1953 Apr;48(2):285–290. doi: 10.1037/h0056264. [DOI] [PubMed] [Google Scholar]
  21. Tansella M., Zimmermann Tansella C., Ferrario L., Preziati L., Tognoni G., Lader M. Plasma concentrations of diazepam, noradiazepam and amylobarbitone after short-term treatment of anxious patients. Pharmakopsychiatr Neuropsychopharmakol. 1978 Mar;11(2):68–75. doi: 10.1055/s-0028-1094564. [DOI] [PubMed] [Google Scholar]
  22. Tansella M., Zimmermann-Tansella C., Lader M. The residual effects of N-desmethyldiazepam in patients. Psychopharmacologia. 1974;38(1):81–90. doi: 10.1007/BF00421290. [DOI] [PubMed] [Google Scholar]
  23. WYSS S., MAEDER A. MOGADON, EIN NEUARTIGES SCHLAFMITTEL. Schweiz Med Wochenschr. 1965 Mar 6;95:338–342. [PubMed] [Google Scholar]
  24. Zimmermann-Tansella C., Tansella M., Lader M. The effects of chlordesmethyldiazepam on behavioral performance and subjective judgment in normal subjects. J Clin Pharmacol. 1976 Oct;16(10 Pt 1):481–488. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES